HLA-B13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients
HLA-B*13:01 allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several studies. Dapsone hydroxylamine (DDS-NHOH), an active metabolite of dapsone, has been believed to be responsible for DHS. However, studies hav...
Saved in:
Published in | Frontiers in immunology Vol. 12; p. 661135 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
04.05.2021
|
Subjects | |
Online Access | Get full text |
ISSN | 1664-3224 1664-3224 |
DOI | 10.3389/fimmu.2021.661135 |
Cover
Loading…
Abstract | HLA-B*13:01
allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several studies. Dapsone hydroxylamine (DDS-NHOH), an active metabolite of dapsone, has been believed to be responsible for DHS. However, studies have not highlighted the importance of other genetic polymorphisms in dapsone-induced severe cutaneous adverse reactions (SCAR). We investigated the association of
HLA
alleles and cytochrome P450 (CYP) alleles with dapsone-induced SCAR in Thai non-leprosy patients. A prospective cohort study, 16 Thai patients of dapsone-induced SCARs (5 SJS-TEN and 11 DRESS) and 9 Taiwanese patients of dapsone-induced SCARs (2 SJS-TEN and 7 DRESS), 40 dapsone-tolerant controls, and 470 general Thai population were enrolled.
HLA
class I and II alleles were genotyped using polymerase chain reaction-sequence specific oligonucleotides (PCR-SSOs).
CYP2C9
,
CYP2C19
, and
CYP3A4
genotypes were determined by the TaqMan real-time PCR assay. We performed computational analyses of dapsone and DDS-NHOH interacting with
HLA-B*13:01
and
HLA-B*13:02
alleles by the molecular docking approach. Among all the
HLA
alleles, only
HLA-B*13:01
allele was found to be significantly associated with dapsone-induced SCARs (OR = 39.00, 95% CI = 7.67–198.21, p = 5.3447 × 10
−7
), SJS-TEN (OR = 36.00, 95% CI = 3.19–405.89, p = 2.1657 × 10
−3
), and DRESS (OR = 40.50, 95% CI = 6.38–257.03, p = 1.0784 × 10
−5
) as compared to dapsone-tolerant controls. Also
, HLA-B*13:01
allele was strongly associated with dapsone-induced SCARs in Asians (OR = 36.00, 95% CI = 8.67–149.52, p = 2.8068 × 10
−7
) and Taiwanese (OR = 31.50, 95% CI = 4.80–206.56, p = 2.5519 × 10
−3
). Furthermore, dapsone and DDS-NHOH fit within the extra-deep sub pocket of the antigen-binding site of the
HLA-B*13:01
allele and change the antigen-recognition site. However, there was no significant association between genetic polymorphism of cytochrome P450 (
CYP2C9
,
CYP2C19
, and
CYP3A4
) and dapsone-induced SCARs (SJS-TEN and DRESS). The results of this study support the specific genotyping of the
HLA-B*13:01
allele to avoid dapsone-induced SCARs including SJS-TEN and DRESS before initiating dapsone therapy in the Asian population. |
---|---|
AbstractList | HLA-B*13:01 allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several studies. Dapsone hydroxylamine (DDS-NHOH), an active metabolite of dapsone, has been believed to be responsible for DHS. However, studies have not highlighted the importance of other genetic polymorphisms in dapsone-induced severe cutaneous adverse reactions (SCAR). We investigated the association of HLA alleles and cytochrome P450 (CYP) alleles with dapsone-induced SCAR in Thai non-leprosy patients. A prospective cohort study, 16 Thai patients of dapsone-induced SCARs (5 SJS-TEN and 11 DRESS) and 9 Taiwanese patients of dapsone-induced SCARs (2 SJS-TEN and 7 DRESS), 40 dapsone-tolerant controls, and 470 general Thai population were enrolled. HLA class I and II alleles were genotyped using polymerase chain reaction-sequence specific oligonucleotides (PCR-SSOs). CYP2C9, CYP2C19, and CYP3A4 genotypes were determined by the TaqMan real-time PCR assay. We performed computational analyses of dapsone and DDS-NHOH interacting with HLA-B*13:01 and HLA-B*13:02 alleles by the molecular docking approach. Among all the HLA alleles, only HLA-B*13:01 allele was found to be significantly associated with dapsone-induced SCARs (OR = 39.00, 95% CI = 7.67-198.21, p = 5.3447 × 10-7), SJS-TEN (OR = 36.00, 95% CI = 3.19-405.89, p = 2.1657 × 10-3), and DRESS (OR = 40.50, 95% CI = 6.38-257.03, p = 1.0784 × 10-5) as compared to dapsone-tolerant controls. Also, HLA-B*13:01 allele was strongly associated with dapsone-induced SCARs in Asians (OR = 36.00, 95% CI = 8.67-149.52, p = 2.8068 × 10-7) and Taiwanese (OR = 31.50, 95% CI = 4.80-206.56, p = 2.5519 × 10-3). Furthermore, dapsone and DDS-NHOH fit within the extra-deep sub pocket of the antigen-binding site of the HLA-B*13:01 allele and change the antigen-recognition site. However, there was no significant association between genetic polymorphism of cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) and dapsone-induced SCARs (SJS-TEN and DRESS). The results of this study support the specific genotyping of the HLA-B*13:01 allele to avoid dapsone-induced SCARs including SJS-TEN and DRESS before initiating dapsone therapy in the Asian population.HLA-B*13:01 allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several studies. Dapsone hydroxylamine (DDS-NHOH), an active metabolite of dapsone, has been believed to be responsible for DHS. However, studies have not highlighted the importance of other genetic polymorphisms in dapsone-induced severe cutaneous adverse reactions (SCAR). We investigated the association of HLA alleles and cytochrome P450 (CYP) alleles with dapsone-induced SCAR in Thai non-leprosy patients. A prospective cohort study, 16 Thai patients of dapsone-induced SCARs (5 SJS-TEN and 11 DRESS) and 9 Taiwanese patients of dapsone-induced SCARs (2 SJS-TEN and 7 DRESS), 40 dapsone-tolerant controls, and 470 general Thai population were enrolled. HLA class I and II alleles were genotyped using polymerase chain reaction-sequence specific oligonucleotides (PCR-SSOs). CYP2C9, CYP2C19, and CYP3A4 genotypes were determined by the TaqMan real-time PCR assay. We performed computational analyses of dapsone and DDS-NHOH interacting with HLA-B*13:01 and HLA-B*13:02 alleles by the molecular docking approach. Among all the HLA alleles, only HLA-B*13:01 allele was found to be significantly associated with dapsone-induced SCARs (OR = 39.00, 95% CI = 7.67-198.21, p = 5.3447 × 10-7), SJS-TEN (OR = 36.00, 95% CI = 3.19-405.89, p = 2.1657 × 10-3), and DRESS (OR = 40.50, 95% CI = 6.38-257.03, p = 1.0784 × 10-5) as compared to dapsone-tolerant controls. Also, HLA-B*13:01 allele was strongly associated with dapsone-induced SCARs in Asians (OR = 36.00, 95% CI = 8.67-149.52, p = 2.8068 × 10-7) and Taiwanese (OR = 31.50, 95% CI = 4.80-206.56, p = 2.5519 × 10-3). Furthermore, dapsone and DDS-NHOH fit within the extra-deep sub pocket of the antigen-binding site of the HLA-B*13:01 allele and change the antigen-recognition site. However, there was no significant association between genetic polymorphism of cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) and dapsone-induced SCARs (SJS-TEN and DRESS). The results of this study support the specific genotyping of the HLA-B*13:01 allele to avoid dapsone-induced SCARs including SJS-TEN and DRESS before initiating dapsone therapy in the Asian population. HLA-B*13:01 allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several studies. Dapsone hydroxylamine (DDS-NHOH), an active metabolite of dapsone, has been believed to be responsible for DHS. However, studies have not highlighted the importance of other genetic polymorphisms in dapsone-induced severe cutaneous adverse reactions (SCAR). We investigated the association of HLA alleles and cytochrome P450 (CYP) alleles with dapsone-induced SCAR in Thai non-leprosy patients. A prospective cohort study, 16 Thai patients of dapsone-induced SCARs (5 SJS-TEN and 11 DRESS) and 9 Taiwanese patients of dapsone-induced SCARs (2 SJS-TEN and 7 DRESS), 40 dapsone-tolerant controls, and 470 general Thai population were enrolled. HLA class I and II alleles were genotyped using polymerase chain reaction-sequence specific oligonucleotides (PCR-SSOs). CYP2C9 , CYP2C19 , and CYP3A4 genotypes were determined by the TaqMan real-time PCR assay. We performed computational analyses of dapsone and DDS-NHOH interacting with HLA-B*13:01 and HLA-B*13:02 alleles by the molecular docking approach. Among all the HLA alleles, only HLA-B*13:01 allele was found to be significantly associated with dapsone-induced SCARs (OR = 39.00, 95% CI = 7.67–198.21, p = 5.3447 × 10 −7 ), SJS-TEN (OR = 36.00, 95% CI = 3.19–405.89, p = 2.1657 × 10 −3 ), and DRESS (OR = 40.50, 95% CI = 6.38–257.03, p = 1.0784 × 10 −5 ) as compared to dapsone-tolerant controls. Also , HLA-B*13:01 allele was strongly associated with dapsone-induced SCARs in Asians (OR = 36.00, 95% CI = 8.67–149.52, p = 2.8068 × 10 −7 ) and Taiwanese (OR = 31.50, 95% CI = 4.80–206.56, p = 2.5519 × 10 −3 ). Furthermore, dapsone and DDS-NHOH fit within the extra-deep sub pocket of the antigen-binding site of the HLA-B*13:01 allele and change the antigen-recognition site. However, there was no significant association between genetic polymorphism of cytochrome P450 ( CYP2C9 , CYP2C19 , and CYP3A4 ) and dapsone-induced SCARs (SJS-TEN and DRESS). The results of this study support the specific genotyping of the HLA-B*13:01 allele to avoid dapsone-induced SCARs including SJS-TEN and DRESS before initiating dapsone therapy in the Asian population. allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several studies. Dapsone hydroxylamine (DDS-NHOH), an active metabolite of dapsone, has been believed to be responsible for DHS. However, studies have not highlighted the importance of other genetic polymorphisms in dapsone-induced severe cutaneous adverse reactions (SCAR). We investigated the association of alleles and cytochrome P450 (CYP) alleles with dapsone-induced SCAR in Thai non-leprosy patients. A prospective cohort study, 16 Thai patients of dapsone-induced SCARs (5 SJS-TEN and 11 DRESS) and 9 Taiwanese patients of dapsone-induced SCARs (2 SJS-TEN and 7 DRESS), 40 dapsone-tolerant controls, and 470 general Thai population were enrolled. class I and II alleles were genotyped using polymerase chain reaction-sequence specific oligonucleotides (PCR-SSOs). , , and genotypes were determined by the TaqMan real-time PCR assay. We performed computational analyses of dapsone and DDS-NHOH interacting with and alleles by the molecular docking approach. Among all the alleles, only allele was found to be significantly associated with dapsone-induced SCARs (OR = 39.00, 95% CI = 7.67-198.21, p = 5.3447 × 10 ), SJS-TEN (OR = 36.00, 95% CI = 3.19-405.89, p = 2.1657 × 10 ), and DRESS (OR = 40.50, 95% CI = 6.38-257.03, p = 1.0784 × 10 ) as compared to dapsone-tolerant controls. Also allele was strongly associated with dapsone-induced SCARs in Asians (OR = 36.00, 95% CI = 8.67-149.52, p = 2.8068 × 10 ) and Taiwanese (OR = 31.50, 95% CI = 4.80-206.56, p = 2.5519 × 10 ). Furthermore, dapsone and DDS-NHOH fit within the extra-deep sub pocket of the antigen-binding site of the allele and change the antigen-recognition site. However, there was no significant association between genetic polymorphism of cytochrome P450 ( , , and ) and dapsone-induced SCARs (SJS-TEN and DRESS). The results of this study support the specific genotyping of the allele to avoid dapsone-induced SCARs including SJS-TEN and DRESS before initiating dapsone therapy in the Asian population. HLA-B*13:01 allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several studies. Dapsone hydroxylamine (DDS-NHOH), an active metabolite of dapsone, has been believed to be responsible for DHS. However, studies have not highlighted the importance of other genetic polymorphisms in dapsone-induced severe cutaneous adverse reactions (SCAR). We investigated the association of HLA alleles and cytochrome P450 (CYP) alleles with dapsone-induced SCAR in Thai non-leprosy patients. A prospective cohort study, 16 Thai patients of dapsone-induced SCARs (5 SJS-TEN and 11 DRESS) and 9 Taiwanese patients of dapsone-induced SCARs (2 SJS-TEN and 7 DRESS), 40 dapsone-tolerant controls, and 470 general Thai population were enrolled. HLA class I and II alleles were genotyped using polymerase chain reaction-sequence specific oligonucleotides (PCR-SSOs). CYP2C9, CYP2C19, and CYP3A4 genotypes were determined by the TaqMan real-time PCR assay. We performed computational analyses of dapsone and DDS-NHOH interacting with HLA-B*13:01 and HLA-B*13:02 alleles by the molecular docking approach. Among all the HLA alleles, only HLA-B*13:01 allele was found to be significantly associated with dapsone-induced SCARs (OR = 39.00, 95% CI = 7.67–198.21, p = 5.3447 × 10−7), SJS-TEN (OR = 36.00, 95% CI = 3.19–405.89, p = 2.1657 × 10−3), and DRESS (OR = 40.50, 95% CI = 6.38–257.03, p = 1.0784 × 10−5) as compared to dapsone-tolerant controls. Also, HLA-B*13:01 allele was strongly associated with dapsone-induced SCARs in Asians (OR = 36.00, 95% CI = 8.67–149.52, p = 2.8068 × 10−7) and Taiwanese (OR = 31.50, 95% CI = 4.80–206.56, p = 2.5519 × 10−3). Furthermore, dapsone and DDS-NHOH fit within the extra-deep sub pocket of the antigen-binding site of the HLA-B*13:01 allele and change the antigen-recognition site. However, there was no significant association between genetic polymorphism of cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) and dapsone-induced SCARs (SJS-TEN and DRESS). The results of this study support the specific genotyping of the HLA-B*13:01 allele to avoid dapsone-induced SCARs including SJS-TEN and DRESS before initiating dapsone therapy in the Asian population. |
Author | Satapornpong, Patompong Konyoung, Parinya Jantararoungtong, Thawinee Tassaneeyakul, Wichittra Khunarkornsiri, Usanee Chung, Wen-Hung Jinda, Pimonpan Rerknimitr, Pawinee Naisbitt, Dean Klaewsongkram, Jettanong Koomdee, Napatrupron Rungrotmongkol, Thanyada Rerkpattanapipat, Ticha Roonghiranwat, Thapana Pirmohamed, Munir Ariyachaipanich, Manasalak Sukasem, Chonlaphat Pratoomwun, Jirawat Mahakkanukrauh, Ajanee Wantavornprasert, Kittipong Wang, Chuang-Wei Amornpinyo, Warayuwadee Saksit, Niwat Nakkam, Nontaya Tempark, Therdpong |
AuthorAffiliation | 6 Division of Dermatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand 2 Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital , Bangkok , Thailand 14 Department of Medicine, Faculty of Medicine, Khon Kaen University , Khon Kaen , Thailand 21 Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool , Liverpool , United Kingdom 3 Division of General Pharmacy Practice, Department of Pharmaceutical Care, College of Pharmacy, Rangsit University , Pathum Thani , Thailand 4 Department of Clinical Chemistry, Faculty of Medical Technology, Huachiew Chalermprakiet University , Samut Prakan , Thailand 25 Genomic Medicine Core Laboratory, Chang Gung Memorial Hospital , Linkou , Taiwan 15 Division of Dermatology, Department of Internal Medicine, Khon Kaen Hospital , Khon Kaen , Thailand 1 Division of Pharmacogenomics and Personalized Medicine, Department of Pa |
AuthorAffiliation_xml | – name: 18 Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital (CGMH) , Taipei , Taiwan – name: 3 Division of General Pharmacy Practice, Department of Pharmaceutical Care, College of Pharmacy, Rangsit University , Pathum Thani , Thailand – name: 7 Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand – name: 12 Pharmacy Unit, Udon Thani Hospital , Udon Thani , Thailand – name: 1 Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University , Bangkok , Thailand – name: 9 Department of Pharmacology, Faculty of Medicine, Khon Kaen University , Khon Kaen , Thailand – name: 10 Biocatalyst and Environmental Biotechnology Research Unit, Department of Biochemistry, Faculty of Science, Chulalongkorn University , Bangkok , Thailand – name: 15 Division of Dermatology, Department of Internal Medicine, Khon Kaen Hospital , Khon Kaen , Thailand – name: 14 Department of Medicine, Faculty of Medicine, Khon Kaen University , Khon Kaen , Thailand – name: 8 King Chulalongkorn Memorial Hospital, Thai Red Cross Society , Bangkok , Thailand – name: 11 Program in Bioinformatics and Computational Biology, Graduated School, Chulalongkorn University , Bangkok , Thailand – name: 22 Skin Center, Ruampaet Dr.ANAN Hospital , Surin , Thailand – name: 23 Department of Pediatrics, Prapokklao Hospital , Chantaburi , Thailand – name: 19 Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Memorial Hospital , Linkou , Taiwan – name: 2 Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital , Bangkok , Thailand – name: 26 The Thai Severe Cutaneous Adverse Drug Reaction (THAI-SCAR) Research Group , Bangkok , Thailand – name: 4 Department of Clinical Chemistry, Faculty of Medical Technology, Huachiew Chalermprakiet University , Samut Prakan , Thailand – name: 20 Department of Dermatology, Xiamen Chang Gung Hospital , Xiamen , China – name: 25 Genomic Medicine Core Laboratory, Chang Gung Memorial Hospital , Linkou , Taiwan – name: 24 Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital , Keelung , Taiwan – name: 17 Division of Allergy Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University , Bangkok , Thailand – name: 6 Division of Dermatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand – name: 5 The Skin and Allergy Research Unit, Chulalongkorn University , Bangkok , Thailand – name: 16 Division of Dermatology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand – name: 13 Unit of Excellence on Pharmacogenomic Pharmacokinetic and Pharmacotherapeutic Researches (UPPER), School of Pharmaceutical Sciences, University of Phayao , Phayao , Thailand – name: 21 Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool , Liverpool , United Kingdom |
Author_xml | – sequence: 1 givenname: Patompong surname: Satapornpong fullname: Satapornpong, Patompong – sequence: 2 givenname: Jirawat surname: Pratoomwun fullname: Pratoomwun, Jirawat – sequence: 3 givenname: Pawinee surname: Rerknimitr fullname: Rerknimitr, Pawinee – sequence: 4 givenname: Jettanong surname: Klaewsongkram fullname: Klaewsongkram, Jettanong – sequence: 5 givenname: Nontaya surname: Nakkam fullname: Nakkam, Nontaya – sequence: 6 givenname: Thanyada surname: Rungrotmongkol fullname: Rungrotmongkol, Thanyada – sequence: 7 givenname: Parinya surname: Konyoung fullname: Konyoung, Parinya – sequence: 8 givenname: Niwat surname: Saksit fullname: Saksit, Niwat – sequence: 9 givenname: Ajanee surname: Mahakkanukrauh fullname: Mahakkanukrauh, Ajanee – sequence: 10 givenname: Warayuwadee surname: Amornpinyo fullname: Amornpinyo, Warayuwadee – sequence: 11 givenname: Usanee surname: Khunarkornsiri fullname: Khunarkornsiri, Usanee – sequence: 12 givenname: Therdpong surname: Tempark fullname: Tempark, Therdpong – sequence: 13 givenname: Kittipong surname: Wantavornprasert fullname: Wantavornprasert, Kittipong – sequence: 14 givenname: Pimonpan surname: Jinda fullname: Jinda, Pimonpan – sequence: 15 givenname: Napatrupron surname: Koomdee fullname: Koomdee, Napatrupron – sequence: 16 givenname: Thawinee surname: Jantararoungtong fullname: Jantararoungtong, Thawinee – sequence: 17 givenname: Ticha surname: Rerkpattanapipat fullname: Rerkpattanapipat, Ticha – sequence: 18 givenname: Chuang-Wei surname: Wang fullname: Wang, Chuang-Wei – sequence: 19 givenname: Dean surname: Naisbitt fullname: Naisbitt, Dean – sequence: 20 givenname: Wichittra surname: Tassaneeyakul fullname: Tassaneeyakul, Wichittra – sequence: 21 givenname: Manasalak surname: Ariyachaipanich fullname: Ariyachaipanich, Manasalak – sequence: 22 givenname: Thapana surname: Roonghiranwat fullname: Roonghiranwat, Thapana – sequence: 23 givenname: Munir surname: Pirmohamed fullname: Pirmohamed, Munir – sequence: 24 givenname: Wen-Hung surname: Chung fullname: Chung, Wen-Hung – sequence: 25 givenname: Chonlaphat surname: Sukasem fullname: Sukasem, Chonlaphat |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34017337$$D View this record in MEDLINE/PubMed |
BookMark | eNp9Uktv1DAQtlARLaU_gAvykUsWO3acmAPSsjy60iIqKGdrYk9al2y82MlK_Hu8TalaDvhia_w9PJ7vOTkawoCEvORsIUSj33R-u50WJSv5QinORfWEnHClZCHKUh49OB-Ts5RuWF5SCyGqZ-RYSMZrIeoT4s83y-I9F_Qt43SdKNCLiM7b0e-RfoH4EyMNHf0Au5Tti_XgJouOfsc9RqSraYQBw5To0uVCQvoNIXPDkKgf6OU1eHoBo8dhTC_I0w76hGd3-yn58enj5eq82Hz9vF4tN4WtBB8LpRTo1goFrpSWi1KCqjsU2urGNW1T6aopK1CiZqqVSgJTucxl1QCTjQBxStazrgtwY3bRbyH-NgG8uS2EeGUgjt72aFwHVdeKttXWSmyllpWteeM0c62zFWatd7PWbmq36GzuI0L_SPTxzeCvzVXYm4YLpmqeBV7fCcTwa8I0mq1PFvt-_jZT5p5L3tT6AH310Ove5O-sMoDPABtDShG7ewhn5hAJcxsJc4iEmSOROfU_HOtHOAwoP9f3_2H-AU5Eu0o |
CitedBy_id | crossref_primary_10_1111_bcp_15054 crossref_primary_10_1016_j_heliyon_2024_e26713 crossref_primary_10_3389_fphar_2023_1183491 crossref_primary_10_1186_s12929_022_00845_8 crossref_primary_10_3389_fitd_2022_893653 crossref_primary_10_1007_s00251_022_01264_7 crossref_primary_10_1016_j_hlife_2023_10_003 crossref_primary_10_1080_03602532_2025_2453521 crossref_primary_10_1080_17425255_2021_1946514 crossref_primary_10_3389_fmed_2023_1187937 crossref_primary_10_1016_j_jaip_2022_04_027 crossref_primary_10_4049_jimmunol_2200531 crossref_primary_10_1080_17425255_2025_2455388 crossref_primary_10_1097_JD9_0000000000000178 crossref_primary_10_1007_s13671_021_00348_z crossref_primary_10_3389_fphar_2022_886377 crossref_primary_10_3390_ph14111077 crossref_primary_10_1097_FPC_0000000000000517 crossref_primary_10_1016_j_isci_2023_107391 crossref_primary_10_1093_pnasnexus_pgae140 crossref_primary_10_7759_cureus_62269 crossref_primary_10_3389_fphar_2022_867490 crossref_primary_10_3389_fphar_2022_891838 crossref_primary_10_3390_medicina59010056 crossref_primary_10_1007_s11882_023_01109_7 crossref_primary_10_1097_ACI_0000000000000914 crossref_primary_10_1016_j_heliyon_2024_e34977 crossref_primary_10_1016_j_jaip_2022_02_004 crossref_primary_10_1080_17512433_2022_2100345 crossref_primary_10_3390_ijms26020680 crossref_primary_10_1080_13696998_2023_2270868 crossref_primary_10_1016_j_jaci_2022_12_005 crossref_primary_10_3389_falgy_2024_1481281 crossref_primary_10_3389_fphar_2022_954596 crossref_primary_10_3390_biomedicines11010177 |
Cites_doi | 10.1016/S0190-9622(96)90667-2 10.1080/14740338.2020.1796965 10.1016/j.alit.2016.04.001 10.1186/s13601-015-0073-8 10.1038/jid.2013.192 10.1097/FPC.0000000000000306 10.1258/004947507781524700 10.1056/NEJMoa1213096 10.1590/S0104-42302012000300003 10.1016/j.jdermsci.2017.08.007 10.1038/s41598-019-46668-w 10.3349/ymj.2016.57.1.118 10.1001/archderm.129.1.92 10.2340/00015555-1268 10.1093/hmg/ddq537 10.1056/NEJMoa1013297 10.1111/j.1365-4632.2010.04593.x 10.1007/s00403-013-1409-7 10.4103/0378-6323.57718 10.1592/phco.24.9.856.36106 10.1111/j.1346-8138.2010.01196.x 10.1001/jamadermatol.2019.2609 10.3390/cancers11040437 10.1080/17425255.2018.1441285 10.4103/0022-3859.81865 10.5415/apallergy.2015.5.2.59 10.1038/srep04862 10.1001/jamadermatol.2017.6484 10.1146/annurev-pharmtox-010611-134701 10.1016/j.therap.2016.12.009 10.1097/00008571-200011000-00005 10.1097/FPC.0000000000000153 10.3389/fphar.2020.00078 10.2217/pgs.12.108 10.1038/428486a 10.12788/j.sder.0059 10.1056/NEJM199411103311906 10.1111/all.13769 10.1001/jama.2014.14148 10.1016/j.jaci.2011.12.990 10.1111/j.1533-2500.2011.00479.x 10.5935/0103-5053.20140168 10.1111/jcpt.12048 10.1111/j.1365-2133.2012.11074.x 10.1590/S0365-05962012000300013 10.1371/journal.pntd.0008746 10.5935/0305-7518.20010009 10.1097/FPC.0000000000000211 10.1001/jama.286.18.2270 10.1038/clpt.2013.5 10.1159/000448217 10.1067/mjd.2001.114733 10.1016/s0198-8859(01)00298-1 10.4269/ajtmh.16-0628 10.1503/cmaj.111152 10.1111/j.1365-2133.2006.07284.x |
ContentType | Journal Article |
Copyright | Copyright © 2021 Satapornpong, Pratoomwun, Rerknimitr, Klaewsongkram, Nakkam, Rungrotmongkol, Konyoung, Saksit, Mahakkanukrauh, Amornpinyo, Khunarkornsiri, Tempark, Wantavornprasert, Jinda, Koomdee, Jantararoungtong, Rerkpattanapipat, Wang, Naisbitt, Tassaneeyakul, Ariyachaipanich, Roonghiranwat, Pirmohamed, Chung and Sukasem. Copyright © 2021 Satapornpong, Pratoomwun, Rerknimitr, Klaewsongkram, Nakkam, Rungrotmongkol, Konyoung, Saksit, Mahakkanukrauh, Amornpinyo, Khunarkornsiri, Tempark, Wantavornprasert, Jinda, Koomdee, Jantararoungtong, Rerkpattanapipat, Wang, Naisbitt, Tassaneeyakul, Ariyachaipanich, Roonghiranwat, Pirmohamed, Chung and Sukasem 2021 Satapornpong, Pratoomwun, Rerknimitr, Klaewsongkram, Nakkam, Rungrotmongkol, Konyoung, Saksit, Mahakkanukrauh, Amornpinyo, Khunarkornsiri, Tempark, Wantavornprasert, Jinda, Koomdee, Jantararoungtong, Rerkpattanapipat, Wang, Naisbitt, Tassaneeyakul, Ariyachaipanich, Roonghiranwat, Pirmohamed, Chung and Sukasem |
Copyright_xml | – notice: Copyright © 2021 Satapornpong, Pratoomwun, Rerknimitr, Klaewsongkram, Nakkam, Rungrotmongkol, Konyoung, Saksit, Mahakkanukrauh, Amornpinyo, Khunarkornsiri, Tempark, Wantavornprasert, Jinda, Koomdee, Jantararoungtong, Rerkpattanapipat, Wang, Naisbitt, Tassaneeyakul, Ariyachaipanich, Roonghiranwat, Pirmohamed, Chung and Sukasem. – notice: Copyright © 2021 Satapornpong, Pratoomwun, Rerknimitr, Klaewsongkram, Nakkam, Rungrotmongkol, Konyoung, Saksit, Mahakkanukrauh, Amornpinyo, Khunarkornsiri, Tempark, Wantavornprasert, Jinda, Koomdee, Jantararoungtong, Rerkpattanapipat, Wang, Naisbitt, Tassaneeyakul, Ariyachaipanich, Roonghiranwat, Pirmohamed, Chung and Sukasem 2021 Satapornpong, Pratoomwun, Rerknimitr, Klaewsongkram, Nakkam, Rungrotmongkol, Konyoung, Saksit, Mahakkanukrauh, Amornpinyo, Khunarkornsiri, Tempark, Wantavornprasert, Jinda, Koomdee, Jantararoungtong, Rerkpattanapipat, Wang, Naisbitt, Tassaneeyakul, Ariyachaipanich, Roonghiranwat, Pirmohamed, Chung and Sukasem |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.3389/fimmu.2021.661135 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1664-3224 |
ExternalDocumentID | oai_doaj_org_article_dfa5fb3bb9cc4eb4945c718d90dbdc5e PMC8130671 34017337 10_3389_fimmu_2021_661135 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Medical Research Council grantid: MR/L006758/1 – fundername: Medical Research Council grantid: G0700654 |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM CGR CUY CVF ECM EIF IPNFZ NPM RIG 7X8 5PM |
ID | FETCH-LOGICAL-c531t-666a9bc36ad24c1324a67fe39c98d8b8595825a63706b464a06d8b1458a0483a3 |
IEDL.DBID | M48 |
ISSN | 1664-3224 |
IngestDate | Wed Aug 27 01:31:26 EDT 2025 Thu Aug 21 14:03:24 EDT 2025 Fri Jul 11 13:13:52 EDT 2025 Sat May 31 02:07:53 EDT 2025 Thu Apr 24 22:58:44 EDT 2025 Tue Jul 01 01:32:46 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | HLA-B13:01 HLA class I and II alleles Thais and Taiwaneses cytochrome P450 dapsone-induced severe cutaneous adverse reactions |
Language | English |
License | Copyright © 2021 Satapornpong, Pratoomwun, Rerknimitr, Klaewsongkram, Nakkam, Rungrotmongkol, Konyoung, Saksit, Mahakkanukrauh, Amornpinyo, Khunarkornsiri, Tempark, Wantavornprasert, Jinda, Koomdee, Jantararoungtong, Rerkpattanapipat, Wang, Naisbitt, Tassaneeyakul, Ariyachaipanich, Roonghiranwat, Pirmohamed, Chung and Sukasem. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c531t-666a9bc36ad24c1324a67fe39c98d8b8595825a63706b464a06d8b1458a0483a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Reviewed by: Mayumi Ueta, Kyoto Prefectural University of Medicine, Japan; Teresa Bellon, University Hospital La Paz Research Institute (IdiPAZ), Spain Edited by: Luis Eduardo Coelho Andrade, Federal University of São Paulo, Brazil This article was submitted to Cytokines and Soluble Mediators in Immunity, a section of the journal Frontiers in Immunology |
OpenAccessLink | https://doaj.org/article/dfa5fb3bb9cc4eb4945c718d90dbdc5e |
PMID | 34017337 |
PQID | 2531218791 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_dfa5fb3bb9cc4eb4945c718d90dbdc5e pubmedcentral_primary_oai_pubmedcentral_nih_gov_8130671 proquest_miscellaneous_2531218791 pubmed_primary_34017337 crossref_primary_10_3389_fimmu_2021_661135 crossref_citationtrail_10_3389_fimmu_2021_661135 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-05-04 |
PublicationDateYYYYMMDD | 2021-05-04 |
PublicationDate_xml | – month: 05 year: 2021 text: 2021-05-04 day: 04 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Frontiers in immunology |
PublicationTitleAlternate | Front Immunol |
PublicationYear | 2021 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Rao (B4) 2001; 72 Zhao (B56) 2019; 74 Satapornpong (B41) 2020; 11 Park (B40) 2016; 57 Bastuji-Garin (B30) 1993; 129 Krismawati (B36) 2020; 14 Harp (B8) 2014; 33 Park (B37) 2020; 19 Wozel (B52) 2014; 306 Dao (B58) 2015; 5 Then (B18) 2011; 29 Peyriere (B14) 2006; 155 Kulkantrakorn (B20) 2012; 12 Tempark (B27) 2017; 27 Mehta (B19) 2009; 75 Wang (B25) 2013; 133 Negrini (B49) 2017; 72 Oliveira (B29) 2014; 25 Kongpan (B48) 2015; 25 Tangamornsuksan (B50) 2018; 154 Pandey (B5) 2007; 37 Lorenz (B55) 2012; 92 Barvaliya (B46) 2011; 57 Sullivan (B15) 2018; 14 Aihara (B12) 2011; 38 Pavlos (B35) 2012; 13 Mahalapbutr (B33) 2019; 11 Cao (B43) 2001; 62 Ho (B53) 2011; 183 Sousa-Pinto (B9) 2016; 170 Ueta (B31) 2014; 4 Wei (B57) 2012; 129 Zhu (B1) 2001; 45 Mahalapbutr (B32) 2019; 9 Hiransuthikul (B7) 2016; 65 McCormack (B22) 2011; 364 Criado (B13) 2012; 87 Amstutz (B42) 2013; 94 Zhang (B26) 2013; 369 Roujeau (B47) 1994; 331 Bharadwaj (B34) 2012; 52 Schrijvers (B39) 2015; 5 Ozeki (B21) 2011; 20 Prussick (B3) 1996; 35 Marotti (B10) 2012; 58 Pirmohamed (B54) 2000; 10 Shen (B6) 2011; 50 Lee (B11) 2012; 167 Tingle (B28) 1997; 283 Watanabe (B51) 2017; 88 Brackett (B45) 2004; 24 Ghimire (B44) 2013; 38 Liu (B38) 2019; 155 Phillips (B16) 2001; 286 Chung (B17) 2004; 428 Wang (B2) 2017; 96 Chung (B23) 2014; 312 Tassaneeyakul (B24) 2016; 26 |
References_xml | – volume: 35 year: 1996 ident: B3 article-title: Dapsone Hypersensitivity Syndrome publication-title: J Am Acad Dermatol doi: 10.1016/S0190-9622(96)90667-2 – volume: 19 year: 2020 ident: B37 article-title: The HLA-B*13:01 and the Dapsone Hypersensitivity Syndrome in Korean and Asian Populations: Genotype- and Meta-Analyses publication-title: Expert Opin Drug Saf doi: 10.1080/14740338.2020.1796965 – volume: 65 year: 2016 ident: B7 article-title: Drug-Induced Hypersensitivity Syndrome/Drug Reaction With Eosinophilia and Systemic Symptoms (Dihs/Dress): 11 Years Retrospective Study in Thailand publication-title: Allergol Int doi: 10.1016/j.alit.2016.04.001 – volume: 5 start-page: 5 year: 2015 ident: B39 article-title: Pathogenesis and Diagnosis of Delayed-Type Drug Hypersensitivity Reactions, From Bedside to Bench and Back publication-title: Clin Transl Allergy doi: 10.1186/s13601-015-0073-8 – volume: 133 year: 2013 ident: B25 article-title: Association Between Hla-B*1301 and Dapsone-Induced Hypersensitivity Reactions Among Leprosy Patients in China publication-title: J Invest Dermatol doi: 10.1038/jid.2013.192 – volume: 27 year: 2017 ident: B27 article-title: Dapsone-Induced Severe Cutaneous Adverse Drug Reactions are Strongly Linked With Hla-B*13: 01 Allele in the Thai Population publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0000000000000306 – volume: 37 year: 2007 ident: B5 article-title: Mortality Due to Dapsone Hypersensitivity Syndrome Complicating Multi-Drug Therapy for Leprosy in Nepal publication-title: Trop Doct doi: 10.1258/004947507781524700 – volume: 369 year: 2013 ident: B26 article-title: HLA-B*13:01 and the Dapsone Hypersensitivity Syndrome publication-title: N Engl J Med doi: 10.1056/NEJMoa1213096 – volume: 58 year: 2012 ident: B10 article-title: Severe Cutaneous Adverse Reactions (Scar) Syndromes publication-title: Rev Assoc Med Bras doi: 10.1590/S0104-42302012000300003 – volume: 88 year: 2017 ident: B51 article-title: A Docking Model of Dapsone Bound to HLA-B*13:01 Explains the Risk of Dapsone Hypersensitivity Syndrome publication-title: J Dermatol Sci doi: 10.1016/j.jdermsci.2017.08.007 – volume: 9 start-page: 1 year: 2019 ident: B32 article-title: Atomistic Mechanisms Underlying the Activation of the G Protein-Coupled Sweet Receptor Heterodimer by Sugar Alcohol Recognition publication-title: Sci Rep doi: 10.1038/s41598-019-46668-w – volume: 57 year: 2016 ident: B40 article-title: Hla Allele Frequencies in 5802 Koreans: Varied Allele Types Associated With SJS/TEN According to Culprit Drugs publication-title: Yonsei Med J doi: 10.3349/ymj.2016.57.1.118 – volume: 129 year: 1993 ident: B30 article-title: Clinical Classification of Cases of Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome, and Erythema Multiforme publication-title: Arch Dermatol doi: 10.1001/archderm.129.1.92 – volume: 92 year: 2012 ident: B55 article-title: Hypersensitivity Reactions to Dapsone: A Systematic Review publication-title: Acta Derm Venereol doi: 10.2340/00015555-1268 – volume: 29 year: 2011 ident: B18 article-title: Frequency of the HLA-B*1502 Allele Contributing to Carbamazepine-Induced Hypersensitivity Reactions in a Cohort of Malaysian Epilepsy Patients publication-title: Asian Pac J Allergy Immunol – volume: 20 year: 2011 ident: B21 article-title: Genome-Wide Association Study Identifies Hla-a*3101 Allele as a Genetic Risk Factor for Carbamazepine-Induced Cutaneous Adverse Drug Reactions in Japanese Population publication-title: Hum Mol Genet doi: 10.1093/hmg/ddq537 – volume: 364 year: 2011 ident: B22 article-title: Hla-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans publication-title: N Engl J Med doi: 10.1056/NEJMoa1013297 – volume: 50 start-page: 57 year: 2011 ident: B6 article-title: Causes of Death Among Active Leprosy Patients in China publication-title: Int J Dermatol doi: 10.1111/j.1365-4632.2010.04593.x – volume: 306 year: 2014 ident: B52 article-title: Dapsone in Dermatology and Beyond publication-title: Arch Dermatol Res doi: 10.1007/s00403-013-1409-7 – volume: 75 year: 2009 ident: B19 article-title: Association of HLA-B*1502 Allele and Carbamazepine-Induced Stevens–Johnson Syndrome Among Indians publication-title: Indian J Dermatol Venereol Leprol doi: 10.4103/0378-6323.57718 – volume: 283 year: 1997 ident: B28 article-title: Comparison of the Metabolism and Toxicity of Dapsone in Rat, Mouse and Man publication-title: J Pharmacol Exp Ther – volume: 24 year: 2004 ident: B45 article-title: Likelihood and Mechanisms of Cross-Allergenicity Between Sulfonamide Antibiotics and Other Drugs Containing a Sulfonamide Functional Group publication-title: Pharmacotherapy doi: 10.1592/phco.24.9.856.36106 – volume: 38 year: 2011 ident: B12 article-title: Pharmacogenetics of Cutaneous Adverse Drug Reactions publication-title: J Dermatol doi: 10.1111/j.1346-8138.2010.01196.x – volume: 155 year: 2019 ident: B38 article-title: Evaluation of Prospective Hla-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy publication-title: JAMA Dermatol doi: 10.1001/jamadermatol.2019.2609 – volume: 11 start-page: 1 year: 2019 ident: B33 article-title: Butoxy Mansonone G Inhibits STAT3 and Akt Signaling Pathways in Non-Small Cell Lung Cancers: Combined Experimental and Theoretical Investigations publication-title: Cancers (Basel) doi: 10.3390/cancers11040437 – volume: 14 year: 2018 ident: B15 article-title: Implications of HLA-allele Associations for the Study of Type Iv Drug Hypersensitivity Reactions publication-title: Expert Opin Drug Metab Toxicol doi: 10.1080/17425255.2018.1441285 – volume: 57 year: 2011 ident: B46 article-title: Drug-Induced Stevens-Johnson Syndrome (Sjs), Toxic Epidermal Necrolysis (TEN), and SJS-TEN Overlap: A Multicentric Retrospective Study publication-title: J Postgrad Med doi: 10.4103/0022-3859.81865 – volume: 5 start-page: 59 year: 2015 ident: B58 article-title: Recent Advances of Pharmacogenomics in Severe Cutaneous Adverse Reactions: Immune and Nonimmune Mechanisms publication-title: Asia Pac Allergy doi: 10.5415/apallergy.2015.5.2.59 – volume: 4 start-page: 1 year: 2014 ident: B31 article-title: Independent Strong Association of HLA-A*02:06 and HLA-B*44:03 With Cold Medicine-Related Stevens-Johnson Syndrome With Severe Mucosal Involvement publication-title: Sci Rep doi: 10.1038/srep04862 – volume: 154 year: 2018 ident: B50 article-title: Association Between Hla-B*1301 and Dapsone-Induced Cutaneous Adverse Drug Reactions: A Systematic Review and Meta-Analysis publication-title: JAMA Dermatol doi: 10.1001/jamadermatol.2017.6484 – volume: 52 year: 2012 ident: B34 article-title: Drug Hypersensitivity and Human Leukocyte Antigens of the Major Histocompatibility Complex publication-title: Annu Rev Pharmacol Toxicol doi: 10.1146/annurev-pharmtox-010611-134701 – volume: 72 year: 2017 ident: B49 article-title: Pharmacogenetics of Hypersensitivity Drug Reactions publication-title: Therapie doi: 10.1016/j.therap.2016.12.009 – volume: 10 year: 2000 ident: B54 article-title: Association Analysis of Drug Metabolizing Enzyme Gene Polymorphisms in HIV-positive Patients With Co-Trimoxazole Hypersensitivity publication-title: Pharmacogenetics doi: 10.1097/00008571-200011000-00005 – volume: 25 year: 2015 ident: B48 article-title: Candidate HLA Genes for Prediction of Co-Trimoxazole-Induced Severe Cutaneous Reactions publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0000000000000153 – volume: 11 start-page: 1 year: 2020 ident: B41 article-title: Genetic Diversity of HLA Class I and Class Ii Alleles in Thai Populations: Contribution to Genotype-Guided Therapeutics publication-title: Front Pharmacol doi: 10.3389/fphar.2020.00078 – volume: 13 year: 2012 ident: B35 article-title: HLA and Pharmacogenetics of Drug Hypersensitivity publication-title: Pharmacogenomics doi: 10.2217/pgs.12.108 – volume: 428 start-page: 486 year: 2004 ident: B17 article-title: Medical Genetics: A Marker for Stevens-Johnson Syndrome publication-title: Nature doi: 10.1038/428486a – volume: 33 start-page: 17 year: 2014 ident: B8 article-title: Severe Cutaneous Adverse Reactions Impact of Immunology Genetics and Pharmacology publication-title: Semin Cutan Med Surg doi: 10.12788/j.sder.0059 – volume: 331 year: 1994 ident: B47 article-title: Severe Adverse Cutaneous Reactions to Drugs publication-title: N Engl J Med doi: 10.1056/NEJM199411103311906 – volume: 74 year: 2019 ident: B56 article-title: Dapsone- and Nitroso Dapsone-Specific Activation of T Cells From Hypersensitive Patients Expressing the Risk Allele Hla-B*13:01 publication-title: Allergy doi: 10.1111/all.13769 – volume: 312 year: 2014 ident: B23 article-title: Genetic Variants Associated With Phenytoin-Related Severe Cutaneous Adverse Reactions publication-title: JAMA doi: 10.1001/jama.2014.14148 – volume: 129 year: 2012 ident: B57 article-title: Direct Interaction Between HLA-B and Carbamazepine Activates T Cells in Patients With Stevens-Johnson Syndrome publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2011.12.990 – volume: 12 year: 2012 ident: B20 article-title: Hla-B*1502 Strongly Predicts Carbamazepine-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Thai Patients With Neuropathic Pain publication-title: Pain Pract doi: 10.1111/j.1533-2500.2011.00479.x – volume: 25 year: 2014 ident: B29 article-title: Clinical Applications and Methemoglobinemia Induced by Dapsone publication-title: J Braz Chem Soc doi: 10.5935/0103-5053.20140168 – volume: 38 start-page: 196 year: 2013 ident: B44 article-title: An Evidence-Based Approach for Providing Cautionary Recommendations to Sulfonamide-Allergic Patients and Determining Cross-Reactivity Among Sulfonamide-Containing Medications publication-title: J Clin Pharm Ther doi: 10.1111/jcpt.12048 – volume: 167 year: 2012 ident: B11 article-title: The Role of Prior Corticosteroid Use on the Clinical Course of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Case-Control Analysis of Patients Selected From the Multinational EuroSCAR and RegiSCAR Studies publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2012.11074.x – volume: 87 year: 2012 ident: B13 article-title: Drug Reaction With Eosinophilia and Systemic Symptoms (Dress) / Drug-induced Hypersensitivity Syndrome (Dihs): A Review of Current Concepts publication-title: Bras Dermatol doi: 10.1590/S0365-05962012000300013 – volume: 14 start-page: 1 year: 2020 ident: B36 article-title: Validation Study of HLA-B*13:01 as a Biomarker of Dapsone Hypersensitivity Syndrome in Leprosy Patients in Indonesia publication-title: PloS Negl Trop Dis doi: 10.1371/journal.pntd.0008746 – volume: 72 start-page: 57 year: 2001 ident: B4 article-title: Increase in the Incidence of Dapsone Hypersensitivity Syndrome an Appraisal publication-title: Lepr Rev doi: 10.5935/0305-7518.20010009 – volume: 26 year: 2016 ident: B24 article-title: Associations Between Hla Class I and Cytochrome P450 2c9 Genetic Polymorphisms and Phenytoin-Related Severe Cutaneous Adverse Reactions in a Thai Population publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0000000000000211 – volume: 286 year: 2001 ident: B16 article-title: Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic Review publication-title: JAMA doi: 10.1001/jama.286.18.2270 – volume: 94 year: 2013 ident: B42 article-title: HLA-A 31:01 and HLA-B 15:02 as Genetic Markers for Carbamazepine Hypersensitivity in Children publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2013.5 – volume: 170 year: 2016 ident: B9 article-title: HLA and Delayed Drug-Induced Hypersensitivity publication-title: Int Arch Allergy Immunol doi: 10.1159/000448217 – volume: 45 year: 2001 ident: B1 article-title: Dapsone and Sulfones in Dermatology: Overview and Update publication-title: J Am Acad Dermatol doi: 10.1067/mjd.2001.114733 – volume: 62 year: 2001 ident: B43 article-title: Analysis of the Frequencies of HLA-A, B, and C Alleles and Haplotypes in the Five Major Ethnic Groups of the United States Reveals High Levels of Diversity in These Loci and Contrasting Distribution Patterns in These Populations publication-title: Hum Immunol doi: 10.1016/s0198-8859(01)00298-1 – volume: 96 year: 2017 ident: B2 article-title: A Review on Dapsone Hypersensitivity Syndrome Among Chinese Patients With an Emphasis on Preventing Adverse Drug Reactions With Genetic Testing publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.16-0628 – volume: 183 year: 2011 ident: B53 article-title: Considerations When Prescribing Trimethoprim-Sulfamethoxazole publication-title: CMAJ doi: 10.1503/cmaj.111152 – volume: 155 year: 2006 ident: B14 article-title: Variability in the Clinical Pattern of Cutaneous Side-Effects of Drugs With Systemic Symptoms: Does a DRESS Syndrome Really Exist publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2006.07284.x |
SSID | ssj0000493335 |
Score | 2.4479978 |
Snippet | HLA-B*13:01
allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several... allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several studies.... HLA-B*13:01 allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 661135 |
SubjectTerms | Adolescent Adult Aged Alleles Asian People - statistics & numerical data Child Child, Preschool Cytochrome P-450 Enzyme System - genetics cytochrome P450 Dapsone - adverse effects dapsone-induced severe cutaneous adverse reactions Female Genetic Association Studies Genetic Markers Genotype HLA class I and II alleles HLA-B Antigens - classification HLA-B Antigens - genetics HLA-B13:01 Humans Immunology Male Middle Aged Molecular Docking Simulation Polymorphism, Genetic Prospective Studies Skin - drug effects Skin - pathology Thais and Taiwaneses Young Adult |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1baxQxFA5SEHwR63ValQg-CbGTSTKZ-NYrq6gUbaFvIZczdMRuy87ug__ek2S77oroi6-ZhAnnnCTnIyffR8hrHXsDXnWsC0EziTk981wDawKOkKAgZkmWT5_bybn8cKEu1qS-Uk1YoQcuhtuLvVO9F96bECR4aaQKuJ9GU0cfg4K0--KZtwamvpW8VwihyjUmojCz1w9XVwvEgw1_i0cSz_Juvw6izNf_pyTz91rJtcPn5AG5v8wa6X6Z7Ta5A9OH5G7RkfzxiAyTj_vsgAv6rub0_UgdPZ2lC5i0ldH0Ggdm9LqnRy6VfgBLch0BIv0KGMdADxeYIML1YqRZnXkE-gXKc4eRDlN6dukGelroV8fH5Pzk-OxwwpYaCizg6pozRCfO-CBaFxsZEHpK1-oehAmmi51P7GaIEV0rdN162UpXt9jMpepcIpt34gnZmuLUnhEaTI0ORSSug5LAMXfzuvdNML7p-r7zFalvDWrDkmA86Vx8twg0kg9s9oFNPrDFBxV5sxpyU9g1_tb5IHlp1TERY-cGDBe7DBf7r3CpyKtbH1tcSOl2pJjYNmivJmmv84o8LT5f_UogCtVC6IrojWjYmMvml-lwmcm6O55AGd_5H5PfJfeSPXK9pXxOtuazBbzAnGjuX-bw_wmrPgy- priority: 102 providerName: Directory of Open Access Journals |
Title | HLA-B13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients |
URI | https://www.ncbi.nlm.nih.gov/pubmed/34017337 https://www.proquest.com/docview/2531218791 https://pubmed.ncbi.nlm.nih.gov/PMC8130671 https://doaj.org/article/dfa5fb3bb9cc4eb4945c718d90dbdc5e |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZKERIXxLvhURmJE5JLHDtxgoRQWygLoqiCrrS3yK_QoHa3TXYl-u-ZsbMrFq0QlxwcO3Zmxpn5Yns-Ql4q11Te5CUrrVVMQkzPDFeeZRZaSJ97FyhZjr8Wo7H8PMknW2RJbzUIsN8I7ZBPatyd7_26un4HE_4tIk7wt6-b9uJiAVAv43vgbbjIb5Cb4JgUMjkcD9H-zxgMCxEoN3lRSAamLOM65-anrHmqkNB_UxT692bKP7zT0V1yZwgr6X60g3tky0_vk1uRaPL6AWlHX_bZARf0Tcrpp55qetLhCg1-6yge1_EdnTX0vca9IZ4hn4f1jn73YOieHi4ggvSzRU8DfXPv6Tcfz0P0tJ3S0zPd0pOYn7V_SMZHH04PR2wgWWAWpt-cAXzRlbGi0C6TFrCp1IVqvKhsVbrSYPozAJG6ECotjCykTgso5jIvNWaj1-IR2Z7C0HYItVUKGgeormwuPYfgzqjGZLYyWdk0pUlIuhRobYcM5EiEcV4DEkEd1EEHNeqgjjpIyKtVk8uYfuNflQ9QS6uKmDk7FMy6H_UwEWvX6LwxwpjKWumNrGRuwT-7KnXG2dwn5MVSxzXMNFw-iSKuM5BXhuTsPCGPo85XXQmAqUoIlRC1Zg1rY1m_M23PQjbvkiNq40_-o9-n5Da-bthvKZ-R7Xm38M8hJpqb3fAvAa4fJ3w3WP1vUIULgQ |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HLA-B13+%3A01+Is+a+Predictive+Marker+of+Dapsone-Induced+Severe+Cutaneous+Adverse+Reactions+in+Thai+Patients&rft.jtitle=Frontiers+in+immunology&rft.au=Satapornpong%2C+Patompong&rft.au=Pratoomwun%2C+Jirawat&rft.au=Rerknimitr%2C+Pawinee&rft.au=Klaewsongkram%2C+Jettanong&rft.date=2021-05-04&rft.issn=1664-3224&rft.eissn=1664-3224&rft.volume=12&rft.spage=661135&rft_id=info:doi/10.3389%2Ffimmu.2021.661135&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon |